Oncotarget

Reviews:

Regulation of PD-1/PD-L1 pathway and resistance to PD-1/PDL1 blockade

Jie Bai, Zhitao Gao, Xiang Li, Liang Dong, Weidong Han and Jing Nie _

PDF  |  HTML  |  How to cite  |  Order a Reprint

Oncotarget. 2017; 8:110693-110707. https://doi.org/10.18632/oncotarget.22690

Metrics: PDF 1966 views  |   HTML 3163 views  |   ?  


Abstract

Jie Bai1, Zhitao Gao1, Xiang Li1, Liang Dong1, Weidong Han1 and Jing Nie1

1Department of Molecular Biology and Bio-Therapeutic, School of Life Science, Chinese PLA General Hospital, Beijing 100853, China

Correspondence to:

Jing Nie, email: nnjj2002@163.com

Weidong Han, email: hanwdrsw69@yahoo.com

Keywords: PD-1; PD-L1; resistance; epigenetic; tumor microenvironment

Received: September 30, 2017     Accepted: November 08, 2017     Published: November 25, 2017

ABSTRACT

Immune checkpoint blockades, such as inhibitors against programmed death 1 (PD-1) and its ligand (PD-L1), have received extensive attention in the past decade because of their dramatic clinical outcomes in advanced malignancies. However, both primary and acquired resistance becomes one of the major obstacles, which greatly limits the long-lasting effects and wide application of PD-1/PD-L1 blockade therapy. PD-1/PD-L1 both regulates and is regulated by cellular signaling pathways and epigenetic modification, thus inhibiting the proliferation and effector function of T and B cells. The lack of tumor antigens and effective antigen presentation, aberrant activation of oncogenic pathways, mutations in IFN-γ signaling, immunosuppressive tumor microenvironment such as regulatory T cells, myeloid-derived suppressor cells, M2 macrophages, and immunoinhibitory cytokines can lead to resistance to PD-1/PD-L1 blockade. In this review, we describe PD-1 related signaling pathways, essential factors contributing to the resistance of PD-1 blockade, and discuss strategies to increase the efficacy of immunotherapy. Furthermore, we discuss the possibility of combined epigenetic therapy with PD-1 blockade as a potential promising approach for cancer treatment.


Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.
PII: 22690